Performance of Transcatheter Direct Annuloplasty in Patients With Atrial and Nonatrial Functional Tricuspid Regurgitation

• DOI: 10.1016/j.jcin.2024.04.013
• Publication Date: 2024-06-24T19:28:46Z
• Authors: Jennifer von Stein; Philipp von Stein; Thorsten Gietzen; Jan Althoff; Caroline Hasse; Clemens Metze; Christos Iliadis; Muhammed Gerçek; Daniel Kalbacher; Johannes Kirchner; Felix Rudolph; Benedikt Köll; Volker Rudolph; Stephan Baldus; Roman Pfister; Maria Isabel Körber
• Keywords: Male; Heart Valve Prosthesis Implantation; Aged, 80 and over; Cardiac Catheterization; Time Factors; Ventricular Remodeling; Recovery of Function; Middle Aged; Tricuspid Valve Insufficiency; Cardiac Valve Annuloplasty; Ventricular Function, Left; Treatment Outcome; Phenotype; Risk Factors; Ventricular Function, Right; Humans; Female; Tricuspid Valve; Aged; Retrospective Studies

A novel echocardiography-based definition of atrial functional tricuspid regurgitation (A-FTR) has shown superior outcomes in patients undergoing conservative treatment or tricuspid valve transcatheter edge-to-edge repair. Its prognostic significance for transcatheter tricuspid valve annuloplasty (TTVA) outcomes is unknown.This study sought to investigate prognostic, clinical, and technical implications of A-FTR phenotype in patients undergoing TTVA.This multicenter study investigated clinical and echocardiographic outcomes up to 1 year in 165 consecutive patients who underwent TTVA for A-FTR (characterized by the absence of tricuspid valve tenting, midventricular right ventricular [RV] dilatation, and impaired left ventricular ejection fraction) and nonatrial functional tricuspid regurgitation (NA-FTR).A total of 62 A-FTR and 103 NA-FTR patients were identified, with the latter exhibiting more pronounced RV remodeling. Compared to baseline, the tricuspid regurgitation (TR) grade at discharge was significantly reduced (P < 0.001 for both subtypes), and TR ≤II was achieved more frequently in A-FTR (85.2% vs 60.8%; P = 0.001). Baseline TR grade and A-FTR phenotype were independently associated with TR ≤II at discharge and 30 days. In multivariate analyses, A-FTR phenotype was a strong predictor (OR: 5.8; 95% CI: 2.1-16.1; P < 0.001) of TR ≤II at 30 days. At 1 year, functional class had significantly improved compared to baseline (both P < 0.001). One-year mortality was lower in A-FTR (6.5% vs 23.8%; P = 0.011) without significant differences in heart failure hospitalizations (13.3% vs 22.7%; P = 0.188).Direct TTVA effectively reduces TR in both A-FTR, which is a strong and independent predictor of achieving TR ≤II, and NA-FTR. Even though NA-FTR showed more RV remodeling at baseline, both phenotypes experienced similar symptomatic improvement, emphasizing the benefit of TTVA even in advanced disease stages. Additionally, phenotyping was of prognostic relevance in patients undergoing TTVA.